The TAP Study: Treating People Who Inject Drugs in Community-Based Settings Using a Social Network Approach
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This study will investigate the feasibility of treating people who inject drugs (PWID) with
hepatitis C virus (HCV) in community-based settings with a 12-week course of oral therapy
combination of sofosbuvir plus ledipasvir. It will also measure the effectiveness of using a
social network-based approach to reduce HCV incidence among PWID.
Phase:
Phase 3
Details
Lead Sponsor:
Macfarlane Burnet Institute for Medical Research and Public Health Ltd